What to do with an inheritance

For many, an inheritance represents a once in a lifetime opportunity

CVAC Jan 2025 2.500 call

OPR - OPR Delayed price. Currency in USD

Add to watchlist

1.5600

0.0000

(0.00%)

At close: 03:32PM EDT

Loading interactive chart…

Reuters
GSK buys full rights to COVID, influenza vaccines from CureVac
(Reuters) -British drugmaker GSK said on Wednesday it is restructuring a partnership with German biotech CureVac and will take control of several vaccines the two companies were jointly developing. GSK said it will pay CureVac 400 million euros ($429.44 million) upfront and up to an additional 1.05 billion euros ($1.13 billion) in development, regulatory and sales milestones as well as tiered royalties. The partnership began in 2020 during the COVID-19 pandemic and saw the two companies work together to develop vaccines for infectious diseases using messenger RNA (mRNA) technology.
Simply Wall St.
CureVac N.V. (NASDAQ:CVAC) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates
CureVac N.V. ( NASDAQ:CVAC ) just released its latest quarterly report and things are not looking great. It was a...
Simply Wall St.
CureVac First Quarter 2024 Earnings: Misses Expectations
CureVac ( NASDAQ:CVAC ) First Quarter 2024 Results Key Financial Results Revenue: €12.4m (up 74% from 1Q 2023). Net...